Gut microbiota and metabolite variations in a migraine mouse model

Dan Wang1,2, Xu Liu1,2, Suming Shi1,2

  • 1Ear, Nose, and Throat (ENT) Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.

Insights

Migraine patients show distinct gut bacteria and metabolite differences compared to healthy individuals. These gut microbiome alterations, particularly Lachnospiraceae, may contribute to migraine development, suggesting probiotic therapy as a potential treatment.

Area of Science:

  • Neuroscience
  • Microbiology
  • Metabolomics

Background:

  • Migraine is a common neurological disorder with unclear pathophysiology.
  • Gut microbiota disruptions are linked to various central nervous system disorders.
  • Potential links between gut health, metabolism, and migraine are emerging.

Purpose of the Study:

  • To investigate differences in gut microbiota and metabolites between a migraine mouse model and normal mice.
  • To explore the role of gut microbiome alterations in migraine pathogenesis.
  • To identify potential therapeutic targets for migraine.

Main Methods:

  • Comparative analysis of gut microbial composition in migraine and control mice.
  • Metabolomic profiling to identify differences in gut metabolites.
  • Correlation analysis between microbial abundance and metabolite levels.

Main Results:

  • Significant differences in gut microbial composition were observed between migraine and control mice.
  • Lachnospiraceae was the most prevalent group in the migraine model, while Akkermansiaceae dominated the control group.
  • Distinct alterations in gut metabolites and metabolic pathways were found in migraine mice.

Conclusions:

  • Gut microbiota composition and metabolites differ significantly in migraine models.
  • Specific bacteria like Lachnospiraceae and associated metabolites may play a role in migraine pathogenesis.
  • Probiotic therapy and targeting metabolic pathways are potential future treatments for migraine.